α-Klotho

Alpha-Klotho (Soluble Klotho, sKlotho)

Evidence & Status

  • Preliminary / Experimental
  • Preliminary

At a Glance

A transmembrane glycoprotein first identified through a 1997 mouse-genetics experiment showing a phenotype resembling premature ageing when the gene was disrupted. In a human hemodialysis population, lower circulating soluble Klotho has been associated with higher mortality and cardiovascular events — an observational finding, not a demonstrated anti-aging or treatment effect.

Plain English

Researchers study α-Klotho because a 1997 experiment in mice found that disrupting the Klotho gene produced a phenotype resembling premature ageing — a finding in mice, not people. Scientists are also interested in how Klotho relates to phosphate metabolism through FGF-23 signaling. In one human study of hemodialysis patients, those with lower blood Klotho levels had higher rates of death and cardiovascular events; this is an association seen in a specific patient population, not proof that raising Klotho would help someone, and it doesn't establish a general anti-aging effect. Most of the therapeutic-sounding claims about Klotho remain at the mouse-study or mechanistic stage.

Overview

α-Klotho is a longevity-associated transmembrane glycoprotein, named for the Greek fate-spinner. It was discovered in 1997 when a mouse gene-disruption model unexpectedly produced a phenotype resembling premature ageing (Kuro-o et al., 1997) — a finding in mice, not direct human evidence. The KL gene (UniProt Q9UEF7) encodes a 1,012-amino-acid type I single-pass transmembrane protein expressed predominantly in the kidneys, brain choroid plexus, and parathyroid glands. It exists as a membrane-bound co-receptor for FGF-23 (regulating phosphate/vitamin D homeostasis) and as a soluble circulating protein (sKlotho) shed by ADAM10/17 metalloprotease cleavage. The calculated mass of the unglycosylated precursor is approximately 116,181 Da; the commonly cited ~130 kDa figure reflects the apparent mass of the glycosylated protein on gel electrophoresis, not the calculated sequence mass. In a human hemodialysis cohort, lower circulating soluble Klotho was associated with higher mortality and cardiovascular events (Memmos et al., 2019) — an observational association, not evidence of causality or of benefit from Klotho administration. Other proposed roles (Wnt/insulin-IGF-1 signaling suppression, antioxidant activity, cognitive effects) remain preclinical or mechanistic. No human interventional trial of exogenous Klotho protein was identified.

Research Summary

α-Klotho's mouse-genetics evidence base is striking: klotho-deficient mice develop a phenotype resembling premature ageing (Kuro-o et al., 1997), and klotho-overexpressing mice have been reported to live longer — but these are mouse findings, not human evidence. In a human hemodialysis cohort, lower circulating soluble Klotho was independently associated with higher mortality and cardiovascular events (Memmos et al., 2019); this is an observational association in a specific patient population, not a general anti-aging or causal claim, and does not indicate that raising Klotho (by any means) improves outcomes. No human interventional trial of exogenous Klotho protein has been identified. The protein's other proposed roles — Wnt/IGF-1 signaling suppression, antioxidant activity, cognitive and renal protection — remain supported mainly by preclinical and mechanistic work. Current human research is centered on using circulating sKlotho as a biomarker rather than as a therapeutic target.

Research Areas

  • Longevity
  • Aging
  • Cognitive function
  • Renal protection
  • Cardiovascular
  • Phosphate metabolism
  • Neuroprotection

Safety & Risks

Serious Risks

  • Unknown; potential effects on phosphate homeostasis, Wnt signaling, and insulin sensitivity require careful characterization before human use

Reported Side Effects

  • Not established in humans; recombinant sKlotho is generally well-tolerated in animal studies
United States
Research only — no approved therapeutic; recombinant sKlotho protein used exclusively in laboratory and preclinical settings
United Kingdom
Research only
Australia
Research only
Canada
Research only

Citations & Sources